Publications by Dr Patrick Kesteven - ePrints

Browsing publications by Dr Patrick Kesteven.

Newcastle Authors	Title	Year
Dr Kathryn Musgrave Dr Jonathan Scott Dr Wezi Sendama Aaron Gardner Fiona Dewar et al.	Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis	2023
Dr Kathryn Musgrave Jonathan Scott Dr Wezi Sendama Dr Patrick Kesteven Dr Marie-Helene Ruchaud et al.	The differential surface expression of tissue factor between monocyte subsets	2020
Salah Abohelaika Dr Hilary Wynne Dr Peter Avery Dr Patrick Kesteven Professor Farhad Kamali et al.	Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management	2016
Dr Kate Musgrave Professor John Simpson Dr Patrick Kesteven	Is there any clinical or biological difference that distinguishes recurrence from non-recurrence after idiopathic PE?	2016
Dr Patrick Kesteven	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry	2015
Salah Abohelaika Professor Farhad Kamali Dr Peter Avery Dr Patrick Kesteven Dr Hilary Wynne et al.	Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England	2014
Basav Sen Dr Patrick Kesteven Dr Peter Avery	Comparison of D-dimer point of care test (POCT) against current laboratory test in patients with suspected venous thromboembolism (VTE) presenting to the emergency department (ED)	2014
Dr Patrick Kesteven Professor Ann Daly Dr Peter Avery Professor Farhad Kamali	A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study	2013
Dr Patrick Kesteven Julian Leathart Professor Ann Daly Professor Farhad Kamali	A Randomized Trial of Genotype-Guided Dosing of Warfarin	2013
Professor Farhad Kamali Dr Hilary Wynne Dr Patrick Kesteven Dr John Hanley Dr Jing Shen et al.	Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through Vitamin K	2013
Dr Logan Thirugnanasothy Dr Patrick Kesteven Professor John Dark	Pulmonary embolism: Surgical embolectomy is underused	2013
Dr Arun Natarajan Emerita Professor Sally Marshall Dr Patrick Kesteven Dr Janet McComb	Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes	2011
Mohamed Noormohamed Susan Stamp Dr Brian Shenton Dr Patrick Kesteven Dr Noel Carter et al.	Effects of extra corporeal membrane oxygenation (ECMO) on liver function and histology, in a porcine model of uncontrolled non heart beating donor (NHBD)	2010
Dr Montserrat Briz Del Blanco Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Professor Ann Daly et al.	Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study	2010
Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Dr Peter Avery Professor Ann Daly et al.	Individualised oral vitamin K for reversal of warfarin excessive anticoagulation	2009
Dr Jonathan Smout Dr Alexander Dyker Professor Gary Ford Dr Patrick Kesteven Professor Gerard Stansby et al.	Platelet Function Following Acute Cerebral Ischemia	2009
Dr Patrick Kesteven Dr Katherine Talks Dr John Hanley	A retrospective audit of a standard protocol for the rapid reversal of warfarin in patients with intracranial haemorrhage	2007
Dr Patrick Kesteven	Early discharge of patients with pulmonary embolism: a two-phase observational study	2007
Dr Brian Angus Dr Patrick Kesteven	Localized reactive angioendotheliomatosis	2007
Sheryl Mitchell Elizabeth Lingard Dr Patrick Kesteven Professor Andrew McCaskie Craig Gerrand et al.	Venous Thromboembolism in Patients with Primary Bone or Soft-Tissue Sarcomas	2007
Wei Zhang Dr Patrick Kesteven	Which patients with venous thrombosis do not require screening for malignancy? A predictive model to identify patients with VTE at minimal risk of malignancy	2007
James McCaslin Dr Jonathan Smout Dr Patrick Kesteven Professor Gerard Stansby	Oral antiplatelet agents and bleeding risk in relation to major cardiovascular surgery	2006
Dr Patrick Kesteven	Outpatient management of pulmonary embolism: results from the national Multicentre PE study	2006
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Patrick Kesteven Dr Peter Avery et al.	[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Peter Avery Dr Barry King et al.	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen	2005
John Hamilton Dr Jon Smith Dr Jonathan Wallis Dr Patrick Kesteven Dr John O'Sullivan et al.	ABO-incompatible heart transplantation in infants: The Freeman Hospital experience	2004
Professor Farhad Kamali Dr Tayyaba Khan Dr Barry King Dr Patrick Kesteven Peter Wood et al.	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin	2004
Dr Tayyaba Khan Dr Hilary Wynne Dr Peter Avery Dr Patrick Kesteven Professor Farhad Kamali et al.	Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin	2004
Dr Jonathan Smout Dr Alexander Dyker Dr Patrick Kesteven Professor Gerard Stansby	Do soluble and platelet surface P-selectin levels correlate with conventional markers of platelet activation?	2004
Dr Tayyaba Khan Professor Farhad Kamali Dr Patrick Kesteven Dr Peter Avery Dr Hilary Wynne et al.	The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation	2004
Dr Patrick Kesteven	A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation	2003
Dr Patrick Kesteven Ritu Arya	Long haul flights and deep vein thrombosis: Who is at risk?	2003
Dr Hilary Wynne Dr Patrick Kesteven Professor Farhad Kamali	The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life	2003
Dr Patrick Kesteven	Incidence of symptomatic thrombosis in a stable population of 650,000: Travel and other risk factors	2002
Dr Janet McComb Dr Patrick Kesteven Emerita Professor Sally Marshall	QT prolongation in patients with Type 2 diabetes and microalbuminuria	2002
Dr Patrick Kesteven	The role of strain gauge plethysmography in the assessment of patients with suspected deep vein thrombosis	2002
Dr Patrick Kesteven	Clinical risk factors for venous thrombosis associated with air travel	2001
Dr Ahmed Chishti Professor John Dark Dr Patrick Kesteven Dr Hazel Powell Dr Christopher Snowden et al.	Expression of chemokine receptors CXCR1 and CXCR2 during cardiopulmonary bypass	2001
Dr Patrick Kesteven Dr Peter Saunders	Model for assessment of endothelial cell function and viability using the MTT dye test and [3H]	2001
Dr Patrick Kesteven	Superficial thrombophlebitis followed by pulmonary embolism	2001
Professor Farhad Kamali Dr Hilary Wynne Dr Patrick Kesteven	Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans	2001
Dr Akif Gani Dr Patrick Kesteven Dr Richard Lendrum	Aortic stenosis and bleeding from angiodysplasia in elderly patients: Is acquired Von Willebrand's disease the link	1999
Professor Chris Day Dr Patrick Kesteven Professor Ann Daly	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications	1999
Dr Janet McComb Dr Patrick Kesteven Emerita Professor Sally Marshall Professor Graham Jackson	Endothelial dysfunction, disordered coagulation and fibrinolysis in patients with type 2 diabetes and microalbuminuria	1999
Dr Patrick Kesteven Dr Janet McComb Emerita Professor Sally Marshall	Reduced ankle brachial index is strongly linked to albumin excretion rate and white cell count but not to measures of endothelial dysfunction or coagulation in NIDDM	1999
Professor Chris Day Dr Patrick Kesteven Professor Ann Daly	Warfarin dose requirement and CYP2C9 polymorphisms - Reply	1999